Citius Oncology, Inc. (CTOR) Shareholder Equity
- 2026-06-30: Common Stock, Value, IssuedUSD $10.58K; Additional Paid in CapitalUSD $145.48M; Retained Earnings (Accumulated Deficit)USD $-105.11M; Stockholders' Equity Attributable to ParentUSD $40.38M.
- 2026-03-31: Common Stock, Value, IssuedUSD $9.30K; Additional Paid in CapitalUSD $131.44M; Retained Earnings (Accumulated Deficit)USD $-96.18M; Stockholders' Equity Attributable to ParentUSD $35.27M.
- 2025-12-31: Common Stock, Value, IssuedUSD $8.48K; Additional Paid in CapitalUSD $127.98M; Retained Earnings (Accumulated Deficit)USD $-69.57M; Stockholders' Equity Attributable to ParentUSD $58.41M.
- 2025-09-30: Common Stock, Value, IssuedUSD $8.35K; Additional Paid in CapitalUSD $108.90M; Retained Earnings (Accumulated Deficit)USD $-64.04M; Stockholders' Equity Attributable to ParentUSD $44.87M.
Citius Oncology, Inc. Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Common Stock, Value, Issued USD | Additional Paid in Capital USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition USD | Adjustments to Additional Paid in Capital, Other USD | Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs USD |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $10.58K | $145.48M | $-105.11M | $40.38M | 3 month · $3.56M | (m) | (m) |
| 2026-03-31 | $9.30K | $131.44M | $-96.18M | $35.27M | 3 month · $3.53M | (m) | (m) |
| 2025-12-31 | $8.48K | $127.98M | $-69.57M | $58.41M | 3 month · $3.96M | (m) | (m) |
| 2025-09-30 | $8.35K | $108.90M | $-64.04M | $44.87M | 12 month · $8.32M | (m) | (m) |
| 2025-06-30 | $7.16K | $91.43M | $-59.04M | $32.40M | 3 month · $2.13M | (m) | (m) |
| 2025-03-31 | $7.16K | $89.31M | $-53.67M | $35.64M | 3 month · $2.09M | (m) | (m) |
| 2024-12-31 | $7.16K | $87.22M | $-45.94M | $41.29M | 3 month · $1.81M | (m) | (m) |
| 2024-09-30 | $7.16K | $85.41M | $-39.28M | $46.14M | 12 month · $7.50M | 12 month · $37.01M | (m) |
| 2024-06-30 | $167.00 | (m) | $-3.04M | $17.03M | 3 month · $1.96M | (m) | (m) |
| 2024-03-31 | $167.00 | (m) | $-2.46M | $19.85M | 3 month · $1.96M | (m) | (m) |
| 2023-12-31 | $167.00 | (m) | $-1.99M | $22.73M | 3 month · $1.92M | (m) | (m) |
| 2023-09-30 | $6.75K | $43.66M | $-18.13M | $25.54M | 12 month · $1.97M | (m) | (m) |
| 2023-06-30 | $242.00 | (m) | $-2.21K | $-1.97K | (m) | (m) | (m) |
| 2023-03-31 | $242.00 | (m) | $197.34K | $197.59K | (m) | (m) | (m) |
| 2022-12-31 | $242.00 | (m) | $345.27K | $345.51K | (m) | (m) | 12 month · $343.85K |
| 2022-09-30 | $173.00 | $24.83K | $-10.11K | $36.27M | (m) | (m) | (m) |
| 2022-06-30 | (m) | (m) | (m) | $-10.11K | (m) | (m) | (m) |
| 2022-03-31 | (m) | (m) | (m) | $-10.11K | (m) | (m) | (m) |
| 2021-12-31 | $173.00 | $24.83K | $-10.11K | $-10.11K | (m) | (m) | (m) |
| 2021-09-30 | (m) | (m) | (m) | $-10.11K | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | (m) | $-10.11K | (m) | (m) | (m) |
| 2021-03-31 | (m) | (m) | (m) | $-9.39K | (m) | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Anixa Biosciences Inc (ANIX) | United States | $0.096B | |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| Acrivon Therapeutics, Inc. (ACRV) | United States | $0.091B | -1.03 |
| Rallybio Corp (RLYB) | United States | $0.089B | |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B | ||
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B | |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |